A group of experts in oncology investigates the feasibility of combination adjuvant immunotherapy in NSCLC consolidation, assessing the utilization of multiple immune checkpoint inhibitors and scrutinizing the rationale, with a focus on findings from the COAST study and PACIFIC-8 studies.
Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.